Kura Oncology (NASDAQ:KURA) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report released on Monday, MarketBeat.com reports. The firm currently has a $40.00 price target on the stock.

A number of other brokerages also recently issued reports on KURA. Guggenheim started coverage on shares of Kura Oncology in a report on Thursday, September 4th. They set a “neutral” rating for the company. JMP Securities cut their price target on shares of Kura Oncology from $28.00 to $24.00 and set a “market outperform” rating for the company in a report on Monday, August 11th. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Kura Oncology Stock Up 1.5%

KURA stock opened at $9.99 on Monday. The company has a market cap of $867.13 million, a price-to-earnings ratio of -4.42 and a beta of 0.32. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $19.73. The firm has a 50-day moving average of $8.46 and a two-hundred day moving average of $6.93.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.90). The business had revenue of $15.29 million for the quarter, compared to the consensus estimate of $64.95 million. As a group, analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, COO Kathleen Ford sold 6,892 shares of Kura Oncology stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total transaction of $61,614.48. Following the completion of the sale, the chief operating officer directly owned 63,375 shares of the company’s stock, valued at approximately $566,572.50. The trade was a 9.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mollie Leoni sold 12,314 shares of Kura Oncology stock in a transaction on Monday, September 29th. The stock was sold at an average price of $8.94, for a total transaction of $110,087.16. Following the sale, the insider directly owned 158,439 shares of the company’s stock, valued at approximately $1,416,444.66. This trade represents a 7.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,058 shares of company stock worth $697,839 over the last three months. 6.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming acquired a new stake in Kura Oncology during the 1st quarter worth $48,000. Tower Research Capital LLC TRC raised its stake in Kura Oncology by 471.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after acquiring an additional 9,958 shares in the last quarter. Pallas Capital Advisors LLC raised its stake in Kura Oncology by 32.2% during the 2nd quarter. Pallas Capital Advisors LLC now owns 13,304 shares of the company’s stock worth $77,000 after acquiring an additional 3,241 shares in the last quarter. Magnetar Financial LLC acquired a new stake in Kura Oncology during the 1st quarter worth $79,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Kura Oncology during the 2nd quarter worth $80,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.